Suppr超能文献

Sirt1 可预防 K-Ras 驱动的肺癌发生。

Sirt1 protects from K-Ras-driven lung carcinogenesis.

机构信息

Bioactive Products and Metabolic Syndrome Group - BIOPROMET, Madrid Institute for Advanced Studies - IMDEA Food, CEI UAM+CSIC, Madrid, Spain.

GENYAL Nutrigenomic Platform, Madrid Institute for Advanced Studies - IMDEA Food, CEI UAM+CSIC, Madrid, Spain.

出版信息

EMBO Rep. 2018 Sep;19(9). doi: 10.15252/embr.201643879. Epub 2018 Jul 18.

Abstract

The NAD-dependent deacetylase SIRT1 can be oncogenic or tumor suppressive depending on the tissue. Little is known about the role of SIRT1 in non-small cell lung carcinoma (NSCLC), one of the deadliest cancers, that is frequently associated with mutated K-RAS Therefore, we investigated the effect of SIRT1 on K-RAS-driven lung carcinogenesis. We report that SIRT1 protein levels are downregulated by oncogenic K-RAS in a MEK and PI3K-dependent manner in mouse embryo fibroblasts (MEFs), and in human lung adenocarcinoma cell lines. Furthermore, Sirt1 overexpression in mice delays the appearance of K-Ras-driven lung adenocarcinomas, reducing the number and size of carcinomas at the time of death and extending survival. Consistently, lower levels of SIRT1 are associated with worse prognosis in human NSCLCs. Mechanistically, analysis of mouse Sirt1-Tg pneumocytes, isolated shortly after K-Ras activation, reveals that Sirt1 overexpression alters pathways involved in tumor development: proliferation, apoptosis, or extracellular matrix organization. Our work demonstrates a tumor suppressive role of SIRT1 in the development of K-RAS-driven lung adenocarcinomas in mice and humans, suggesting that the SIRT1-K-RAS axis could be a therapeutic target for NSCLCs.

摘要

NAD 依赖的去乙酰化酶 SIRT1 的作用可能致癌,也可能抑癌,具体取决于组织。目前对于 SIRT1 在非小细胞肺癌(NSCLC)中的作用知之甚少,非小细胞肺癌是最致命的癌症之一,通常与突变型 K-RAS 相关。因此,我们研究了 SIRT1 对 K-RAS 驱动的肺癌发生的影响。我们报告称,致癌性 K-RAS 通过 MEK 和 PI3K 依赖性途径下调小鼠胚胎成纤维细胞(MEFs)和人肺腺癌细胞系中的 SIRT1 蛋白水平。此外,Sirt1 在小鼠中的过表达可延迟 K-Ras 驱动的肺腺癌的出现,减少死亡时腺癌的数量和大小,并延长存活时间。一致地,较低水平的 SIRT1 与人类 NSCLC 患者的预后较差相关。从机制上讲,对 K-Ras 激活后不久分离的小鼠 Sirt1-Tg 肺细胞进行分析表明,Sirt1 过表达改变了与肿瘤发生相关的途径:增殖、凋亡或细胞外基质组织。我们的工作表明 SIRT1 在小鼠和人类 K-RAS 驱动的肺腺癌发展中具有抑癌作用,这表明 SIRT1-K-RAS 轴可能是 NSCLC 的治疗靶点。

相似文献

1
Sirt1 protects from K-Ras-driven lung carcinogenesis.
EMBO Rep. 2018 Sep;19(9). doi: 10.15252/embr.201643879. Epub 2018 Jul 18.
3
JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.
Int J Cancer. 2019 Dec 15;145(12):3376-3388. doi: 10.1002/ijc.32624. Epub 2019 Sep 10.
4
Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer.
Exp Mol Med. 2023 Oct;55(10):2220-2237. doi: 10.1038/s12276-023-01091-0. Epub 2023 Oct 2.
5
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
J Exp Clin Cancer Res. 2019 Apr 15;38(1):165. doi: 10.1186/s13046-019-1170-7.
9
Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma.
Cancer Cell. 2013 Nov 11;24(5):603-16. doi: 10.1016/j.ccr.2013.10.003.
10
ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis.
Cancer Gene Ther. 2021 May;28(5):359-374. doi: 10.1038/s41417-020-00245-w. Epub 2020 Oct 17.

引用本文的文献

1
Senotherapy for chronic lung disease.
Pharmacol Rev. 2025 May 28;77(4):100069. doi: 10.1016/j.pharmr.2025.100069.
2
SLC29A1 and SLC29A2 are human nicotinamide cell membrane transporters.
Nat Commun. 2025 Jan 30;16(1):1181. doi: 10.1038/s41467-025-56402-y.
3
Emerging role of sirtuins in non‑small cell lung cancer (Review).
Oncol Rep. 2024 Oct;52(4). doi: 10.3892/or.2024.8786. Epub 2024 Aug 2.
4
Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer.
Exp Mol Med. 2023 Oct;55(10):2220-2237. doi: 10.1038/s12276-023-01091-0. Epub 2023 Oct 2.
5
From targeted therapy to a novel way: Immunogenic cell death in lung cancer.
Front Med (Lausanne). 2022 Dec 23;9:1102550. doi: 10.3389/fmed.2022.1102550. eCollection 2022.
7
Resveratrol's Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism.
Cancers (Basel). 2021 Jan 7;13(2):188. doi: 10.3390/cancers13020188.
8
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy.
Front Cell Dev Biol. 2020 Sep 29;8:576946. doi: 10.3389/fcell.2020.576946. eCollection 2020.
9
Avenanthramide C suppresses hypoxia-induced cyclooxygenase-2 expression through sirtuin1 activation in non-small-cell lung cancer cells.
Anim Cells Syst (Seoul). 2020 Apr 2;24(2):79-83. doi: 10.1080/19768354.2020.1748108. eCollection 2020.
10
ERK Dephosphorylation through MKP1 Deacetylation by SIRT1 Attenuates RAS-Driven Tumorigenesis.
Cancers (Basel). 2020 Apr 8;12(4):909. doi: 10.3390/cancers12040909.

本文引用的文献

1
Collagen prolyl hydroxylase 3 has a tumor suppressive activity in human lung cancer.
Exp Cell Res. 2018 Feb 1;363(1):121-128. doi: 10.1016/j.yexcr.2017.12.020. Epub 2017 Dec 23.
2
Caveolin-1 promotes the tumor suppressor properties of oncogene-induced cellular senescence.
J Biol Chem. 2018 Feb 2;293(5):1794-1809. doi: 10.1074/jbc.M117.815902. Epub 2017 Dec 15.
4
Analysis of the advantages of cis reporters in optimized FACS-Gal.
Cytometry A. 2017 Jul;91(7):721-729. doi: 10.1002/cyto.a.23086. Epub 2017 Apr 4.
5
Prognostic and Predictive Role of Sirtuin1 Expression in Lung Adenocarcinoma.
Clin Lab. 2016 Oct 1;62(10):1989-1994. doi: 10.7754/Clin.Lab.2016.160317.
7
Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers.
Science. 2016 Sep 9;353(6304):1161-5. doi: 10.1126/science.aaf5171.
8
FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies.
Cell Death Discov. 2015 Nov 23;1:15049. doi: 10.1038/cddiscovery.2015.49. eCollection 2015.
9
Oncogenic driver mutations in lung cancer.
Transl Respir Med. 2013 Dec;1(1):6. doi: 10.1186/2213-0802-1-6. Epub 2013 Mar 8.
10
Aurora kinase targeting in lung cancer reduces KRAS-induced transformation.
Mol Cancer. 2016 Feb 3;15:12. doi: 10.1186/s12943-016-0494-6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验